CD33 and acute myeloid leukemia: In contrast, a case report of a 41-year-old male shows that CD33 CAR-T temporarily reduced the number of AML primitive cells in his bone marrow (NCT01864902), prior to disease progression 9 weeks after initiation of the treatment [95].